Wall Street Journal

64x Bio Lands $55 Million for Gene-Therapy Tech

Startup 64x Bio has secured $55 million in a financing round led by venture firm Lifeforce Capital to use its cell line-engineering technology to improve production of gene therapies now under ...
FiercePharma

Harvard offshoot 64x Bio nets $55M in series A funding to expand cell production tech

64x Bio, a fledgling synthetic cell and gene therapy manufacturer, brought in $55 million in a series A round of fundraising. The company, which has about 10 employees and was founded in 2020 out of ...
Business Insider

Here is the 10-slide deck a new biotech company addressing a critical gene-therapy bottleneck used to raise $55 million in just a few months

Every time Allison publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...
Business Wire

64x Bio Emerges from Stealth to Drive an Evolution in Cell and Gene Therapy Manufacturing

SAN FRANCISCO--(BUSINESS WIRE)--64x Bio announced today that they are emerging from stealth and are describing for the first time their proprietary VectorSelect TM platform and vision for the company.